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Calcitonin gene-related peptide has been shown to
modulate in¯ammatory and immune responses in
various systems. Recent studies in our laboratory
and others have shown that intracutaneously injected
calcitonin gene-related peptide impairs the induction
of contact hypersensitivity in mice, and participates
in the pathogenesis of failed contact hypersensitivity
induction after acute, low-dose ultraviolet B radia-
tion. In this study we investigated the ability of
calcitonin gene-related peptide to induce tolerance
in normal and mast cell de®cient mice and we
examined the extent to which calcitonin gene-related
peptide contributes to the tolerance induced by
acute, low-dose ultraviolet B radiation. Calcitonin
gene-related peptide was injected intradermally fol-
lowed by application of 2,4-dinitro-1-¯uorobenzene
to the injected skin surface. Tolerance was assessed
by re-exposing the mice 2 wk later to a second,
sensitizing dose of 2,4-dinitro-1-¯uorobenzene on
uninjected skin. We found that calcitonin gene-
related peptide induced tolerance to 2,4-dinitro-1-
¯uorobenzene in both normal and mast cell de®cient
mice. Calcitonin gene-related peptide-induced toler-
ance was blocked by intradermal injection of a calci-
tonin gene-related peptide antagonist [CGRP-(8-37)]
that selectively blocks the calcitonin gene-related
peptide receptor. Tolerance was also abolished by
intraperitoneally injected anti-interleukin-10, but not
anti-tumor necrosis factor a, antibodies. When 2,4-
dinitro-1-¯uorobenzene was painted on skin into
which splenic dendritic cells pretreated with calcito-
nin gene-related peptide had been injected, tolerance
was observed. Calcitonin gene-related peptide-
treated dendritic cells mixed with anti-interleukin-10
antibody prior to intradermal injection failed to
promote tolerance. Finally, injection of CGRP-(8-37)
into skin that was subsequently exposed to acute,
low-dose ultraviolet B radiation partially prevented
tolerance induced by local application of 2,4-dinitro-
1-¯uorobenzene. These results indicate that calcito-
nin gene-related peptide has the capacity to promote
cutaneous tolerance through an interleukin-10-
dependent mechanism. This mechanism, which does
not require the participation of mast cells, contri-
butes to the tolerance promoted by acute, low-dose
ultraviolet B radiation. Thus, calcitonin gene-related
peptide from cutaneous nerve endings plays a key
role in the local immune aberrations caused by ultra-
violet B radiation. Key words: calcitonin gene-related
peptide/contact hypersensitivity/dendritic cells/skin/toler-
ance. J Invest Dermatol 115:942±948, 2000
T
here is increasing evidence that neural systems play an
important role in regulating the immune system. It
has been reported that nerve endings can be found
anatomically associated with lymphoid tissues (Felton
et al, 1987; Lorton et al, 1991), and that several
neuropeptides are capable of modulating immune responses
(Reichlin, 1988). In the skin, the termini of cutaneous sensory C
®bers contain calcitonin gene-related peptide (CGRP) and
substance P, and come to rest directly on the surfaces of epidermal
Langerhans cells (Hosoi et al, 1993), suggesting that these
neuropeptides might modulate cutaneous antigen-presenting cell
function.
CGRP, a 37 amino acid neuropeptide derived from calcitonin/
CGRP gene by alternative RNA splicing (Arama et al, 1982), is
produced within neurons (Rosenfeld et al, 1991) and, depending
upon dose, has potent vasodilatory properties when injected into
the skin (Brain et al, 1985). Recent studies have demonstrated that
CGRP also has immune-regulatory properties, including inhibition
of proliferative responses of peripheral blood mononuclear cells and
of interleukin-2 (IL-2) production by lymphocytes, and suppression
of induction of delayed-type and contact hypersensitivity (CH)
(Boudard and Bastide, 1991; Wang et al, 1991; Asahina et al, 1995a;
Fox et al, 1997). The immune-regulatory effects of CGRP seem to
be derived from its ability to induce IL-10, to impair the
production of IL-12, and to inhibit B7 expression on antigen-
presenting cells (Dai and Streilein, 1993). Recent studies have
revealed that CGRP is released from cutaneous nerve endings after
ultraviolet B (UVB) radiation to the skin (Benrath et al, 1995;
Niizeki et al, 1997). We have recently reported that impaired CH
that follows a single, low-dose of UVB to UVB-susceptible mice is
mediated by CGRP. To impair CH, CGRP triggers the local
release of tumor necrosis factor a (TNF-a) from dermal mast cells,
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and TNF-a in turn prevents cutaneous antigen-presenting cells
from preparing a suitable hapten-speci®c immunogenic signal that
leads to CH induction (Niizeki et al, 1997).
Acute, low-dose UVB also results in systemic tolerance if hapten
is applied directly to the exposed skin site immediately following
the last dose of radiation (Toews et al, 1980; Shimizu and Streilein,
1994b). We and others have reported that UVB causes the release
of IL-10 in the exposed skin (Ullrich, 1994; Enk et al, 1995; Niizeki
and Streilein, 1997). In particular, although numerous skin cells are
capable of producing IL-10 in response to UVB, we have recently
discovered that mast cells are the most important source of IL-10
that is responsible for hapten-speci®c tolerance after acute, low-
dose UVB (unpublished result). As mast cells have CGRP receptors
(Piotrowski and Foreman, 1986), and as CGRP has already been
implicated in the failed CH that follows acute, low-dose UVB in
UVB-susceptible mice, we wished to determine whether (i) CGRP
is capable of inducing tolerance similar to that promoted by UVB,
(ii) CGRP acts by triggering mast cell degranulation, and (iii) IL-10
is the cytokine responsible for CGRP-dependent tolerance. Our
results indicate that CGRP is capable of promoting hapten-speci®c
tolerance, and that the mechanism involves IL-10 acting on
dendritic antigen-presenting cells. Although mast cells are the
cutaneous source of preformed IL-10 (Thompson-Snipes et al,
1991) that accounts for the deleterious effects of acute, low dose
UVB on CH induction, the ®nding that CGRP can promote
tolerance even in the absence of dermal mast cells implicates other
cutaneous cells in UVB-dependent tolerance.
MATERIALS AND METHODS
Mice C3H/HeN mice (8±12 wk old) were purchased from Taconic
Farms (Germantown, NY) and housed in the animal facility in our
institute. Seven-week-old female mast cell de®cient mice, WBB6F1 (WB-
W/+ 3 C57BL/6-Wv/+)-W/Wv, and normal littermates, WBB6F1+/+,
were purchased from the Jackson Laboratory (Bar Harbor, ME). The
institutional Animal Care and Use Committee approved all animal
procedures. Experimental procedures were carried out with the animals
under general anesthesia achieved by intraperitoneal injection of ketamine
(12.5 mg per ml; Fort Dodge Laboratory, Fort Dodge, IA) and xylazine
(0.125 mg per ml; Phoenix Pharmaceutical, St. Joseph, MO). Each
experimental protocol was repeated at least twice with similar results.
Reagents Rat CGRP and its antagonist, human CGRP-(8-37), were
purchased from Peninsula Laboratory (Belmont, CA). Dinitro¯uoro-
benzene (DNFB) was obtained from Sigma Chemical (St. Louis, MO).
Monoclonal antimouse IL-10 was puri®ed from culture supernatant of
hybridoma J5E-2A5. Anti-TNF-a anti-bovine serum albumin antibodies
and rat IgG1 were obtained from Genzyme (Cambridge, MA).
UVB radiation Shaved abdominal skin was exposed to UVB from a
bank of four FS-20 ¯uorescent lamps with a tube-to-target distance of
46 cm, as previously described (Niizeki and Streilein, 1997). These bulbs
have a broad emission spectrum (250±400 nm) and high output primarily in
the UVB range (290±320 nm). As measured by an IL 700 radiometer with
an SEE 240 UVB photometer (Medko Medical Instrumentarium, Helsinki,
Finland), these lamps delivered an average ¯ux of 1.5 J per m2 per s. Mice
were exposed to UVB for one or four consecutive days at a dose of 400 J
per m2.
Intradermal injection Using a 1.0 ml syringe with a 30 gauge needle,
contents of the syringe were placed within the intradermal space. Successful
inoculation was characterized by the appearance of ¯attened swelling with
de®ned lateral margins immediately beneath the epidermis.
Assessment of tolerance On day 0, 25 ml of 0.5% DNFB in acetone
(185 mg) were applied to the dry-shaved abdominal skin 3 h after the
injection of CGRP. Two weeks later, the same mice received a second
epicutaneous application of DNFB in acetone (185 mg) on dry-shaved
dorsal body-wall skin. Five days later, one ear of each mouse was
challenged by painting with 20 ml of 0.05% DNFB (15 mg). Ear swelling
was measured with an engineer's micrometer (Mitsutoyo, Tokyo, Japan) 24
and 48 h after challenge and was compared with ear thickness before
challenge. The results of representative experiments are presented. In some
experiments, oxazolone was used for second sensitization (2.5 mg) and for
ear challenge (200 mg).
Preparation of dendritic-cell-enriched fractions Spleens were
removed from normal C3H/HeN mice and pressed through nylon mesh
to produce a single cell suspension. Red blood cells were lyzed with Gey's
solution. Dendritic cells were subsequently puri®ed by density gradient
centrifugation as described before (Dai and Streilein, 1993). Brie¯y, a cell
suspension in low-density Percoll solution (d = 1.035) was overlaid on
high-density solution (d = 1.075) and centrifuged at 400 3 g for 20 min at
4°C. The interface fraction was collected and washed with Hank's balanced
salt solution (HBSS). Cells were resuspended in RPMI-1640 medium
supplemented with 10% heat-inactivated fetal bovine serum, 0.1 mM
nonessential amino acid, 1 mM sodium pyruvate, 2 mM glutamine, 10 mM
HEPES, 100 mg per ml streptomycin, and 100 U per ml penicillin and
incubated in a Petri dish for 1 h. Non-adherent cells were discarded and the
dish was extensively washed with HBSS three times, and further cultured
overnight in serum-free RPMI-1640 supplemented with 0.1% bovine
serum albumin and ITS + culture supplement [1 mg per ml iron-free
transferrin, 10 ng per ml linoleic acid, 0.3 ng per ml Na2Se, and 0.2 mg
per ml Fe(NO3)3] (Collaborative Biomedical Products, Bedford, MA) in
the presence or absence of CGRP (100 ng per ml) at 37°C in an
atmosphere of 5% CO2. Floating cells containing dendritic-cell-enriched
cells were collected and washed to remove CGRP.
Measurement of IL-10 To assay culture supernatants for content of IL-
10, CGRP-treated or untreated dendritic cells (5 3 105 cells per well) were
added into 48-well plates in serum-free medium. Cells were cultured for 24
or 48 h at 37°C in an atmosphere of 5% C02, and then culture super-
natants were collected and analyzed by quantitative capture enzyme-linked
immunosorbent assay (ELISA) according to the manufacturer's instruction
(PharMingen, San Diego, CA). Rat monoclonal antibody to mouse IL-10
(JES5-2A5) was used as coating antibody. Biotinylated rat monoclonal
antibody to mouse IL-10 (SXC-1) (PharMingen) was used as detecting
antibody.
Statistical analysis The statistical signi®cance of differences between the
means of each experimental group was determined with Student's t test
(two-tailed). Mean differences were considered to be signi®cant for
p < 0.05. Analyses were performed using StatView 512+ (Abacus
Concepts, Berkeley, CA) on a Macintosh 7500 computer.
RESULTS
CGRP promotes hapten-speci®c tolerance CGRP has been
shown to impair CH induction when the peptide was injected
intradermally at a dose of 530 pmol or higher immediately before
epicutaneous application of DNFB. Therefore, we examined the
tolerance-promoting potential of CGRP using doses similar to
those previously reported. Three hours following injection of
CGRP (530 pmol) into the skin of the abdomen of C3H/HeN
mice, the surface received DNFB (185 mg) in acetone. Two weeks
later, these mice received a second sensitizing dose of DNFB on
dorsal skin. Positive control mice received intradermal injection of
phosphate-buffered saline (PBS), followed by two applications of
DNFB separated by 14 d. When the ears of these mice were
challenged with dilute DNFB (15 mg) 5 d later, CH responses of
CGRP-treated mice were often as intense as those of positive
controls, i.e., tolerance did not regularly follow hapten application
to skin sites that received 530 pmol CGRP (data not shown). We
then conducted a dose-response experiment in which doses as high
as 4240 pmol CGRP were injected intradermally. The results of
one such experiment are displayed in Fig 1(A). Mice that received
intradermal injections containing 1060 and 4240 CGRP mounted
CH responses subsequently that were signi®cantly lower than
positive controls. At lower doses of CGRP (265 pmol and less), CH
responses were not signi®cantly different from positive controls. In
all subsequent experiments, 1060 pmol CGRP was used for
intradermal injections. These results indicate that CGRP
promoted tolerance when DNFB was painted on skin into which
the neuropeptide had been injected 3 h previously.
To determine whether the tolerance-promoting activity of
CGRP was mediated through the neuropeptide's speci®c receptor,
CGRP-(8-37) was used. This peptide sequence, which functions as
an antagonist of CGRP, binds to the CGRP receptor with high
af®nity, preventing signaling by CGRP itself. CGRP, with or
without the antagonist CGRP-(8-37) (1060 pmol), was injected
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into the dermis of abdominal wall skin of normal mice. Three hours
later, DNFB (185 mg) was applied to the site. Two weeks later the
mice received a sensitizing dose of DNFB to previously untreated
skin, and 5 d later their ears were challenged with dilute DNFB.
The results of a representative experiment are presented in
Fig 1(B). As before, mice that ®rst encountered DNFB via
CGRP-injected skin displayed weak ear swelling responses. By
contrast, mice that received an intradermal injection of CGRP plus
its speci®c antagonist acquired CH comparable to positive controls.
We conclude that CGRP promotes tolerance to epicutaneously
applied DNFB by triggering cutaneous cells bearing CGRP
receptors.
Hapten speci®city of tolerance promoted by CGRP We
next examined the hapten speci®city of CGRP-dependent
tolerance. Two groups of mice received DNFB on CGRP-
injected skin. Two weeks later, one group was resensitized with
DNFB through normal back skin. The second group received a
sensitizing dose of oxazolone on back skin. Positive control mice
received an intradermal injection of PBS rather than CGRP. Each
group was ear-challenged 5 d later. Sensitization with oxazolone on
normal skin 2 wk after the ®rst sensitization with DNFB through
CGRP-injected skin resulted in strong ear swelling responses to
oxazolone (Fig 2, group B). On the other hand, mice that ®rst
encountered DNFB through CGRP-injected skin followed by
second sensitization with the same hapten failed to mount intense
CH responses (Fig 2, group D). These results indicate that CGRP
promotes tolerance that is speci®c for the hapten painted
epicutaneously on the injected site.
CGRPpromotes tolerancevia IL-10butnotTNF-a Previous
studies in our laboratory have shown that CGRP acts on mast cells to
cause the prompt release of TNF-a, and that this cytokine in turn
impairs the induction of CH to locally applied haptens (Niizeki et al,
1997). Degranulation of mast cells leads to the release of both TNF-a
and IL-10, and we have recently reported that the tolerance induced
by acute, low dose UVB is mediated by IL-10 (Niizeki and Streilein,
1997). To determine whether either or both of these cytokines are
involved in CGRP-promoted tolerance, we examined the effects of
neutralizing antibodies to IL-10 and TNF-a. Anti-IL-10 monoclonal
antibody or anti-TNF-a antisera were administered intraperitoneally
to normal C3H/HeN mice 6 h before injection of CGRP into the
skin. Three hours later, a sensitizing dose of DNFB was applied to the
injected site. Tolerance was assessed as described above. As the results
presented in Fig 3 reveal, anti-IL-10 monoclonal antibody prevented
tolerance induced by 1060 pmol of CGRP (Fig 3A). Anti-TNF-a
had no similar effect, however (Fig 3B). These results indicate that
IL-10, but not TNF-a, is involved in the mechanism by which
CGRP promotes tolerance.
CGRP promotes tolerance in mast cell de®cient mice As
mentioned above, CGRP impairs CH induction by triggering mast
cells to release TNF-a. Mast cells have been shown to secrete IL-
10 as well as TNF-a in response to various stimuli including UVB.
Therefore, by using mast cell de®cient mice (w/wv), we tested the
possibility that CGRP may promote tolerance through its action on
mast cells. Panels of wild-type or mast cell de®cient mice received
intradermal injections of CGRP prior to DNFB application, and
tolerance was assessed as above. Intradermal injection of CGRP
prior to hapten application resulted in tolerance in both wild-type
and mast cell de®cient mice (Fig 4). These results indicate that
CGRP does not require degranulation of mast cells in order to
promote tolerance. Moreover, these ®ndings imply that when
CGRP promotes tolerance it must act on cells other than mast cells.
Dendritic cells treated in vitro with CGRP promote
tolerance In the tolerance that follows hapten application to
skin exposed to acute, low-dose UVB, cells responsible for
tolerance induction reside within the skin (Kurimoto et al,
Figure 1. CGRP promotes tolerance in C3H/HeN mice. (A) CGRP
promotes tolerance in a dose-dependent fashion. Panels of C3H/HeN mice
received intradermal injections of CGRP at doses of 265, 1060, or
4240 pmol in 200 ml of PBS into shaved abdominal skin. Positive control
mice received PBS injections. Three hours after the injection, 25 ml of 0.5%
DNFB (185 mg) was applied directly on the injected site. (B) CGRP
antagonist inhibits CGRP-promoted tolerance. Panels of C3H/HeN mice
received intradermal injection of CGRP (1060 pmol), CGRP plus its
antagonist [CGRP-(8-37)] (1060 pmol), or PBS. Three hours after the
injection, 25 ml of 0.5% DNFB (185 mg) was applied directly on the
injected site. Two weeks later, all mice received a second application of
the same dose of hapten (185 mg) on dorsal skin. Ear challenges with dilute
DNFB (15 mg) were performed 5 d later, and swelling responses were
assessed 24 h later. Ear swelling responses are presented as mean 6 SEM
(mm) (n = 5). Values signi®cantly lower than positive control (C):
*p < 0.01; **p < 0.001.
Figure 2. CGRP promotes hapten-speci®c tolerance. Panels of C3H/
HeN mice received an intradermal injection of CGRP (1060 pmol) or PBS
(positive controls), followed within 3 h by epicutaneous application of
DNFB (185 mg). Two weeks later, two panels of mice (A, B) received an
immunization with oxazolone and two panels (C, D) received a second
immunization with DNFB on dorsal wall skin. The mice were ear
challenged 5 d later and assayed as described in the caption to Fig 1. An
asterisk indicates that mean ear swelling response was signi®cantly lower
than positive controls, p < 0.001.
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1994a, b). Circumstantial evidence suggests that bone-marrow-
derived antigen-presenting cells may initiate the tolerance. We
therefore examined the possibility that CGRP might promote
tolerance by acting directly on dendritic cells. To test this
possibility, we examined whether dendritic cells could induce
tolerance when they were treated with CGRP in vitro. Dendritic
cells were prepared from spleens of normal mice and cultured
overnight with or without CGRP in serum-free medium in the
presence or absence of the antagonist CGRP-(8-37). We used
100 ng per ml CGRP because this concentration of CGRP has
been shown to inhibit the ability of human peripheral mononuclear
cells to stimulate proliferation of T cells (Fox et al, 1997). Following
overnight incubation, the dendritic cells were harvested, washed,
and injected (2 3 104 cells per injection) intradermally into
abdominal skin. Thirty minutes later, DNFB was painted on the
injected site, and tolerance was assessed as described before. The
results of a representative experiment are presented in Fig 5.
Application of DNFB to the skin of mice that received untreated
dendritic cells, or dendritic cells treated with CGRP plus its
antagonist (Fig 5, groups C, G), failed to promote tolerance. Ear
swelling responses of these mice were similar to positive controls.
Dendritic cells treated with CGRP prior to intradermal injection
and application of DNFB, however, inhibited recipient mice from
developing intense ear swelling responses following a second,
sensitizing dose of DNFB (Fig 5, group D). Thus, CGRP appeared
to act directly on dendritic cells, enabling these cells to promote
hapten-speci®c tolerance in vivo.
Dendritic cells treated with CGRP promote tolerance via an
IL-10-dependentmechanism Considerable evidence implicates
IL-10 in the immune de®cit evoked in skin by acute, low-dose UVB.
We next evaluated whether the tolerance promoted by intradermal
injection of CGRP acted through an IL-10-dependent mechanism.
In the following experiments, dendritic cells were incubated
overnight with CGRP alone, anti-IL-10 antibodies alone, or a
mixture of CGRP + anti-IL-10 antibodies. Thereafter, the cells were
washed and injected (2 3 104 per injection) into abdominal wall skin
of normal mice. DNFB was painted on the site 30 min later, and a
similar dose of DNFB was painted on uninjected skin 2 wk later. Ears
of these mice were challenged with dilute DNFB 5 d later. Ear
swelling responses in a representative experiment are presented in
Fig 6. CH responses of recipients of dendritic cells incubated with
CGRP alone (group D) were reduced compared to positive controls,
whereas responses of recipients of untreated dendritic cells, or
dendritic cells incubated with CGRP plus anti-IL-10 antibodies (or
anti-IL-10 antibodies alone) (groups C, E, and F), were as intense as
Figure 3. Effects of neutralizing anti-IL-10 and anti-TNF-a anti-
bodies on tolerance promoted by CGRP. (A) Neutralizing anti-IL-10
antibody prevents CGRP-induced tolerance. C3H/HeN mice received a
single intraperitoneal injection of 400 mg of rat antimouse IL-10
monoclonal antibody or rat IgG1 (control) 6 h before CGRP injections.
Three hours after intradermal injection of CGRP (1060 pmol), DNFB
(185 mg) was applied to the injected skin (abdominal). (B) Neutralizing
anti-TNF-a antibody fails to prevent CGRP-promoted tolerance. C3H/
HeN mice received a single intraperitoneal injection of anti-TNF-a
antibody (2 3 104 U per animal) or rabbit anti-bovine serum albumin
antibody (control) 6 h before CGRP injections. Three hours after the
injection, DNFB (185 mg) was applied to the injected skin site. Tolerance
was assessed as described in Fig 1. An asterisk indicates mean swelling
responses signi®cantly less than positive controls, *p < 0.05; **p < 0.01.
Figure 4. Tolerance induction by CGRP in mast cell de®cient mice.
Panels of wild-type mice (A) and mast cell de®cient mice (B) were painted
with DNFB (185 mg) on CGRP-injected or PBS-injected abdominal skin.
Tolerance was assessed as described in Fig 1. Mean values signi®cantly
lower than positive control. *p < 0.05, **p < 0.01.
Figure 5. CGRP-treated dendritic cells promote tolerance. Splenic
dendritic cells were prepared from normal C3H/HeN mice and cultured
overnight with CGRP (100 ng per ml) in the presence or absence of
CGRP-(8-37) (200 ng per ml) (E and D, respectively). The cells were
harvested, washed, and injected intradermally (2 3 104 cells per animal)
into abdominal skin of naõÈve C3H/HeN mice. Positive control mice
received untreated dendritic cells (C). Within 30 min, DNFB (185 mg) was
painted on the injected site. Two weeks later these mice plus a panel of
naõÈve mice received an immunizing dose of DNFB (185 mg) on dorsal wall
skin. Five days later the ears were challenged with dilute DNFB and assayed
24 h later for ear swelling. Results are presented according to the caption to
Fig 1. An asterisk indicates mean values signi®cantly lower than positive
control. *p < 0.05; **p < 0.01.
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positive controls. These ®ndings reveal that CGRP-treated dendritic
cells acquire tolerance-promoting properties, and that acquisition of
these properties somehow involves IL-10.
We next examined whether dendritic cells treated with CGRP
were capable of producing IL-10. Dendritic cells pretreated with
CGRP as described above were washed free of excess neuropeptide
and then cultured in serum-free medium for 24 or 48 h.
Supernatants were harvested from these cultures and analyzed by
ELISA for IL-10 content. The results of a representative
experiment are presented in Fig 7. Dendritic cells that were
cultured in the absence of exogenous CGRP produced small
amounts of IL-10. Incubation of dendritic cells with CGRP for 24
and 48 h, however, caused the cells to produce signi®cantly
enhanced amounts of IL-10.
UVB-induced tolerance is dependent in part upon
CGRP UVB of the acute low-dose variety impairs CH
induction at the exposed site through a mechanism in which
CGRP is released from cutaneous nerves. As both impaired CH
induction and hapten-speci®c tolerance result from application of
hapten to skin exposed to acute, low-dose UVB, we next examined
whether the tolerance promoted by UVB was triggered by CGRP
release. Shaved abdominal skin of C3H/HeN mice received an
intradermal injection of the CGRP antagonist (530 or 2120 pmol per
injection). Within 30 min, one panel of mice received the ®rst of four
consecutive daily exposures to UVB. CGRP antagonist was similarly
injectedprior to eachdoseofUVB.For another panel ofmice,CGRP
antagonist was injected intradermally followed by a single (and only)
dose of UVB. UVB control mice received intradermal injections of
PBS rather than CGRP-(8-37). Positive controls received no
intradermal injections. DNFB (185 mg) was painted on the
irradiated and injected skin following the last (or only) exposure to
UVB. Two weeks later these same mice received a second sensitizing
dose of DNFB on shaved dorsal skin, and tolerance was assessed as
described before. The results are presented in Fig 8. As reported
previously, mice exposed to the four daily dose UVB regimen
(Fig 8A) followed by local DNFB application displayed CH
responses not signi®cantly higher than negative controls. By
contrast, intradermal injection of CGRP-(8-37) prior to each UVB
exposure enabled the mice to mount ear swelling responses that were
greater than mice injected with PBS, but less than positive controls,
i.e., intermediate between the negative and the positive controls. The
capacity of CGRP-(8-37) to antagonize UVB was enhanced in a
dose-dependent manner. Similarly, mice whose skin was injected
with PBS and exposed to a single dose of UVB followed by a
sensitizing dose of DNFB displayed tolerance upon subsequent
testing (Fig 8B). Moreover, intradermal injection of CGRP
antagonist partially restored the ability of these mice to resist UVB-
dependent tolerance. We interpret these results to mean that CGRP
participates in the tolerance promoted by acute, low-dose UVB of
both one dose and four dose regimens. The inability of CGRP-(8-37)
Figure 6. CGRP-treated dendritic cells promote tolerance via IL-
10. Splenic dendritic cells were prepared from normal C3H/HeN mice and
cultured overnight in the presence or absence of CGRP (100 ng per ml) (D
and C, respectively). Additional dendritic cells were cultured with anti-IL-
10 antibodies (E) or CGRP + anti-IL-10 (F). The cells were harvested,
washed, and injected (2 3 104 cells per animal) into abdominal skin. DNFB
(185 mg) was painted on the injected skin within 30 min after the injection.
Tolerance was assessed as described in the caption to Fig 1. Mean values
signi®cantly lower than positive control (C). *p < 0.01.
Figure 7. CGRP enhances IL-10 production by dendritic cells.
Dendritic cells were prepared from normal C3H/HeN mice as described in
the caption to Fig 5 and cultured overnight in serum-free medium in the
presence or absence of CGRP (100 ng per ml). The dendritic cells were
harvested, washed, and cultured in serum-free medium for 24 or 48 h.
Supernatants were removed and assessed by ELISA for IL-10 content.
Mean values signi®cantly lower than control. *p < 0.05.
Figure 8. CGRP antagonist partially reverses tolerance induced by
acute, low-dose UVB. Panels of C3H/HeN mice received either four
consecutive daily doses (A) or a single dose (B) of UVB. CGRP-(8-37), a
CGRP antagonist, was injected intradermally into abdominal skin 30 min
prior to each UVB exposure. Mice that received four exposures to UVB
received four injections of CGRP antagonist. Immediately following the
last or only dose of UVB, DNFB (185 mg) was painted on the UVB-
exposed site. Tolerance was assessed as described in the caption to Fig 1.
An asterisk indicates mean values signi®cantly lower than positive control.
*p < 0.05; **p < 0.01.
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to abolish tolerance completely after UVB implies that other
tolerance-promoting factors also contribute.
DISCUSSION
A subset of molecules that are placed on the cutaneous surface give
rise to CH, a systemic immune response that manifests itself by a
delayed in¯ammatory reaction at cutaneous sites at which the
offending molecules are subsequently placed. The term hapten has
been used to identify molecules of this type. As not all molecules
placed on the skin give rise to CH, and as this form of immunity is
thought to be important in the pathogenesis of contact dermatitis,
an important goal of research is to delineate the factors that
determine the haptenic immunogenicity of molecules. Certain
features of haptens, such as their physicochemical properties and
inherent toxicity, contribute to immunogenicity (Grabbe et al,
1996). But there are also features of the skin itself that participate.
Over the recent past evidence has been presented that implicates
neuropeptides released from cutaneous nerves as playing a role in
hapten immunogenicity. Niizeki et al have recently reported that
substance P, acting similarly to an adjuvant, promotes the capacity
of DNFB to induce CH in normal mice. Moreover, the deleterious
effects of acute, low-dose UVB on CH induction can be reversed
by substance P agonists (Niizeki et al, 1999). The C-type nerve
®ber termini in the skin that contain substance P also contain
CGRP (Ansel et al, 1996). Niizeki et al have also shown that
CGRP impairs the induction of CH in a manner similar to UVB,
and CGRP antagonists restore the capacity of UVB-exposed skin
to support the induction of CH by DNFB (Niizeki et al, 1997).
Similarly, Asahina et al (1995a) reported that CGRP impaired CH
induction in mice, and Gillardon et al (1995) reported that a CGRP
antagonist prevented the inhibition of CH induction following
acute, low dose UVB. Thus, neuropeptides from cutaneous nerves
can have a powerful effect on the induction of cutaneous
immunity, especially following cutaneous exposure to UVB.
Acute, low-dose UVB not only impairs CH induction locally,
but this regimen promotes tolerance when hapten is painted on the
exposed site (Toews et al, 1980; Shimizu and Streilein, 1994a;
1994b). Tolerance of this type appears to be dependent upon IL-
10, which is generated within skin after UVB exposure (Ullrich,
1994; Niizeki and Streilein, 1997). The results presented in this
paper provide evidence for a molecular link between UVB
exposure and IL-10-dependent tolerance, and that link appears to
be CGRP. Our evidence indicates that CGRP injected intra-
dermally promoted hapten-speci®c tolerance in normal mice, and
that normal dendritic cells incubated overnight with CGRP
secreted enhanced amounts of IL-10 and acquired tolerance-
promoting qualities. Moreover, the tolerance promoted by CGRP
was mediated by IL-10, as evidenced by the abrogation of tolerance
in CGRP-treated mice that received anti-IL-10 antibodies
systemically. In a similar manner, dendritic cells treated simul-
taneously with CGRP and anti-IL-10 antibodies in vitro failed to
assume tolerance-promoting properties when injected intra-
dermally. Finally, a CGRP antagonist injected into skin immedi-
ately prior to UVB exposure aborted the capacity of locally applied
hapten to induce tolerance, con®rming that CGRP participates in
UVB-dependent tolerance. To our knowledge, this is the ®rst
report to document an effect of CGRP on tolerance induction by
epicutaneously applied haptens, and to link that effect to the
capacity of acute, low-dose UVB to induce hapten-speci®c
tolerance. We propose that acute, low-dose UVB opens a pathway
to systemic, hapten-speci®c tolerance by triggering (directly or
indirectly) cutaneous nerves to release CGRP. We further propose
that CGRP acts directly on cutaneous antigen-presenting cells,
diverting their secretory program away from IL-12 toward IL-10.
As a consequence, IL-10 mediates tolerance induction by acting on
hapten-speci®c T cells ®rst activated in the draining node.
The pathway just described accounts for the ability of CGRP to
induce tolerance in mast cell de®cient mice that we observed in our
studies. But we doubt that this is the only pathway by which
CGRP promotes tolerance in mice with skin containing mast cells.
It is known that normal dermal mast cells contain CGRP receptors
(Piotrowski and Foreman, 1986), and that exposure of these cells to
CGRP causes them to release TNF-a and IL-10 (Benrath et al,
1995). Therefore, it is altogether likely that the CGRP-dependent
tolerance resulting from acute, low-dose UVB emerges from two
immunopathogenic pathways. The ®rst, as described above,
involves a direct effect of CGRP on cutaneous antigen-presenting
cells, causing them to secrete IL-10 rather than IL-12, and the
second involves the ability of CGRP to trigger IL-10 release from
mast cells that further enriches the cutaneous milieu for this
immunosuppressive cytokine. CGRP does not appear to account
for all of the tolerance that is promoted by acute, low-dose UVB,
however. In our experiments, a powerful CGRP antagonist
[CGRP-(8-37)] was only able to achieve a partial reversal of
tolerance when normal mice were treated with acute, low-dose
UVB. As neutralizing anti-IL-10 has been found to abolish UVB-
dependent tolerance completely, there must be another intra-
cutaneous source of IL-10 after UVB, a source that is not triggered
by CGRP. Keratinocytes are known to produce IL-10 within 8±
12 h of UVB, and this may be another source (Ullrich, 1994; Enk
et al, 1995).
The ®nding that CGRP acts directly on dendritic cells to
enhance IL-10 secretion is of considerable interest. Several recent
reports have described a similar effect of CGRP on dendritic cells
and macrophages. Torii et al (1997) demonstrated that CGRP
potentiates IL-10 production by a Langerhans-cell-like line (XS52)
and by lipopolysaccharide-stimulated macrophages. Asahina et al
(1995b) showed that CGRP causes the intracellular accumulation
of cAMP in a variety of cutaneous cells, including Langerhans cells,
and that this was linked to impaired expression of B7-2 by
Langerhans cells. Our results add to this body of knowledge. First,
the response of dendritic cells to CGRP provides evidence that the
morphologic observation of Hoshi et al (that nerve termini
containing CGRP abut directly on the surface of epidermal
Langerhans cells) (Hosoi et al, 1993) has physiologic relevance.
Second, the fact that CGRP-treated cells secrete large amounts of
IL-10 implies that the CGRP receptor transduces a signal that
reaches the IL-10 gene, although it is also possible that dendritic
cells store IL-10 (perhaps in a manner similar to mast cells) and that
some of the secreted IL-10 is released from intracellular stores. As
Niizeki and Streilein (1997) reported that intracutaneously injected
IL-10 induced tolerance that was hapten speci®c, and as dendritic
cells treated with CGRP produce IL-10 and promote tolerance, we
infer that the mechanisms are similar and that the tolerance
promoted by CGRP-treated dendritic cells is hapten speci®c.
Irrespective of the mechanism by which CGRP enhances IL-10
production by dendritic cells, the ®nding that treated dendritic cells
promote tolerance, rather than CH, has important rami®cations
with respect to the immunogenicity of haptens. We have
previously demonstrated that epicutaneous application of DNFB
results in CH that is enhanced by substance P. We have inferred
from this observation that the strong immunogenicity of DNFB
depends, in part, on its ability to cause cutaneous nerves to release
substance P. We do not know whether only substance P is released
in this circumstance, however, as cutaneous nerve termini typically
contain both substance P and CGRP. We speculate that strongly
immunogenic haptens cause the selective release of substance P,
and that poorly immunogenic molecules cause the selective release
of CGRP. Experiments to test this interesting possibility are
currently under way.
It was of interest that dendritic cells treated with CGRP
promoted tolerance when injected intradermally into normal mice.
Following acute, low-dose UVB, the dermis has been reported to
contain a bone-marrow-derived cell that promotes tolerance
induction (Kurimoto et al, 1994a). By depleting skin of phago-
cytic cells (macrophages) and demonstrating that the tolerance-
conferring cell was still present after UVB (Kurimoto et al, 1994b),
the inference was drawn that the responsible cell was a dendritic
cell. We were surprised to ®nd that epicutaneous hapten
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application to skin into which CGRP-treated dendritic cells had
been injected resulted in tolerance, however. In this situation, the
uninjected skin already contained a normal complement of antigen-
presenting cells, and in the absence of exogenous CGRP-treated
dendritic cells, hapten failed to induce tolerance. This reveals that
dendritic cells treated with CGRP and injected intradermally have
a dominant effect on the immune outcome when hapten is applied
epicutaneously. The reasons for this dominance are not immedi-
ately apparent. One possible explanation is that the IL-10 secreted
by the injected cells is able to create a novel, IL-10-rich
microenvironment, in which the functional properties of resident
cutaneous antigen-presenting cells are altered. In support of this
explanation is the observation that intradermal injection of IL-10
generates tolerance if hapten is painted directly on the injected site
(Niizeki and Streilein, 1997). Alternatively, the injected dendritic
cells may migrate to the draining lymph node, in which case their
ability to secrete IL-10 would be able to in¯uence naõÈve T cells ®rst
encountering hapten at that site. It has long been known that the
tolerance promoted by acute, low-dose UVB is mediated by
hapten-speci®c suppressor T cells. Intranodal dendritic cells with
the capacity to secrete large amounts of IL-10 might be the agents
responsible for activating these regulatory T cells (Elmets et al,
1983).
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